Story
Mizuho Highlights 7 Top Healthcare Stocks Ahead of Key 2026 Catalysts

Mizuho has released its updated "Top Picks List" for the U.S. healthcare sector, spotlighting seven companies its analysts believe represent the highest-conviction, catalyst-driven opportunities. The selections, based on bottom-up analysis, span the biotechnology, medical device, and healthcare services industries.
Catalyst-Driven Selections
The list represents investment ideas from Mizuho's U.S. analysts, with conviction levels assessed by comparing the firm's own ratings, price targets, and earnings estimates against Bloomberg consensus data. The selected companies are notable for upcoming clinical trial results, strong product pipelines, or favorable market dynamics.
Biotechnology in Focus
Mizuho's report placed a strong emphasis on biotechnology firms with near-term data readouts and significant market potential. The highlighted companies include:
Ad- Eyepoint Pharmaceuticals (EYPT): Named a top pick for its ophthalmology therapy Duravyu, with pivotal Phase 3 study data expected in August 2026 and later in the year.
- Vaxcyte (PCVX): The firm sees its pneumococcal vaccine candidate as potentially best-in-class, targeting an $8 billion market. Key non-inferiority trial data is anticipated in the fourth quarter of 2026.
- Erasca (ERAS): Highlighted for its RAS inhibitor portfolio, which Mizuho estimates could support risk-adjusted worldwide sales of approximately $6 billion by 2036.
- Arcutis Biotherapeutics (ARQT): Mizuho noted potential upside to the company's 2026 Zoryve sales guidance of $480 million to $495 million.
Devices and Services Outlook
Beyond biotech, Mizuho identified opportunities in medical devices and healthcare providers, citing strong operational performance and strategic positioning.
- AxoGen (AXGN): Following a key license for its Avance Nerve Allograft, Mizuho believes the company's full-year top-line growth could approach 20%, ahead of the current Street forecast of 18%.
- Encompass Health (EHC): The firm pointed to strong demand, evidenced by 78.7% occupancy rates in the first quarter of 2026, and a strategy to significantly increase bed capacity.
- Solventum (SOLV): After a business divestiture, the company is positioned to pay down debt. A proprietary Mizuho survey also indicated strong expected growth in dental patient volume and consumables for 2026.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.